Interacting Drugs |
Ibritumomab vs Antiplatelet Agents |
Security Level |
 |
Mechanism |
Antiplatelet Agents: May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding. |
Management |
Monitor therapy |
Ibritumomab vs Antiplatelet Agents
Post Review about Ibritumomab vs Antiplatelet Agents Click here to cancel reply.
Other Interactions of Ibritumomab
Other Interactions of Antiplatelet Agents
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.